Q1 2026 AxoGen Inc Earnings Call Transcript
Key Points
- Axogen Inc (AXGN) reported a strong first-quarter revenue of $61.5 million, reflecting a 26.6% growth year-over-year.
- The company achieved double-digit growth across all three target markets, demonstrating effective market development strategies.
- Axogen Inc (AXGN) expanded its commercial insurance coverage, with Cigna extending broad coverage to Advance nerve graft for peripheral nerve repair.
- The company ended the quarter with $103.6 million in cash equivalents, restricted cash, and investments, indicating a strong financial position.
- Salesforce productivity exceeded expectations, with an increase in active surgeon count, reflecting broader adoption of nerve care.
- Operating expenses increased to $49 million, up from $36.6 million in the first quarter of 2025, driven by higher compensation costs.
- Net loss for the first quarter was $19.6 million, significantly higher than the net loss of $3.8 million in the first quarter of 2025.
- The company incurred a one-time loss of $16.8 million due to the extinguishment of its debt facility.
- Sales and marketing expenses as a percentage of total revenue increased to 46.6%, reflecting higher investments in commercial strategy.
- Gross margin is expected to face pressure in the second quarter due to the transition to Biologic Advance products.
Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's President and Chief Executive Officer Lindsay Hartley, Chief Financial Officer. Michael will discuss first quarter 2026 financial results and corporate highlights. Lindsay will then provide details on financial performance and overall outlook for the year. This will be followed by a question-and-answer session.
Today's call and presentation is being broadcast live via webcast, which is available on the Investors section of Axogen's website. Following the end of the live call, a replay will be available on the Investors section of the company's website at www.axogeninc.com.
Before we begin, I would like to remind you that during this conference call, management will be making forward-looking statements. Forward-looking statements include statements regarding financial guidance and outlook, clinical development, and regulatory efforts, commercial growth initiatives, reimbursement, and market access efforts.
Training and education
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
